{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=18",
    "query": {
      "condition": "Refractory Malignancy",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 5765,
    "total_pages": 577,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T12:04:01.203Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00087139",
      "title": "Ixabepilone in Treating Patients With Metastatic Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ixabepilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 124,
      "start_date": "2004-09",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2014-05-09",
      "last_synced_at": "2026-11-11T12:04:01.203Z",
      "location_count": 162,
      "location_summary": "Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 114 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00087139"
    },
    {
      "nct_id": "NCT04752722",
      "title": "LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Superficial Bladder Cancer",
        "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ",
        "Non-muscle Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "EG-70 (phase 1)",
          "type": "DRUG"
        },
        {
          "name": "EG-70 (phase 2) Master Protocol",
          "type": "DRUG"
        },
        {
          "name": "Surfactant Bladder Pre-Rinse and EG-70 (Substudy)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "enGene, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2021-04-22",
      "completion_date": "2030-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-11-11T12:04:01.203Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04752722"
    },
    {
      "nct_id": "NCT00669422",
      "title": "ChemoFx® PRO - A Post-Market Data Collection Study",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Uterine Neoplasms",
        "Endometrial Cancer",
        "Vaginal Cancer",
        "Vulvar Cancer",
        "Cervical Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Precision Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 2756,
      "start_date": "2006-10",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2012-10-05",
      "last_synced_at": "2026-11-11T12:04:01.203Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00669422"
    },
    {
      "nct_id": "NCT00478075",
      "title": "Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "samarium Sm 153 lexidronam pentasodium",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2005-09",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2011-05-11",
      "last_synced_at": "2026-11-11T12:04:01.203Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00478075"
    },
    {
      "nct_id": "NCT06846606",
      "title": "Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Acute Myeloid Leukemia (AML)",
        "Refractory Acute Myeloid Leukemia (AML)",
        "Relapsed/Refractory AML",
        "Relapsed Myelodysplastic Syndromes",
        "Refractory Myelodysplastic Syndromes",
        "Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "AUTX-703",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Auron Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2025-05-01",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-11T12:04:01.203Z",
      "location_count": 9,
      "location_summary": "Duarte, California • Tampa, Florida • Buffalo, New York + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06846606"
    },
    {
      "nct_id": "NCT04678336",
      "title": "CD123 Redirected T Cells for AML in Pediatric Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia, in Relapse",
        "Acute Myeloid Leukemia, Pediatric",
        "Acute Myeloid Leukemia, Refractory"
      ],
      "interventions": [
        {
          "name": "CART123 cells; cyclophosphamide; fludarabine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "1 Year to 29 Years"
      },
      "enrollment_count": 12,
      "start_date": "2021-04-02",
      "completion_date": "2025-05-09",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-11-11T12:04:01.203Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04678336"
    },
    {
      "nct_id": "NCT04985604",
      "title": "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Solid Tumor",
        "CRAF Gene Amplification",
        "RAF1 Gene Amplification",
        "BRAF Gene Fusion",
        "BRAF Fusion",
        "CRAF Gene Fusion",
        "CRAF Fusion",
        "RAF1 Gene Fusion",
        "RAF1 Fusion",
        "Thyroid Cancer, Papillary",
        "Spitzoid Melanoma",
        "Pilocytic Astrocytoma",
        "Pilocytic Astrocytoma, Adult",
        "Non Small Cell Lung Cancer",
        "Non-Small Cell Adenocarcinoma",
        "Colorectal Cancer",
        "Pancreatic Acinar Carcinoma",
        "Spitzoid Malignant Melanoma",
        "Bladder Cancer",
        "Bladder Urothelial Carcinoma",
        "MAP Kinase Family Gene Mutation",
        "RAF Mutation"
      ],
      "interventions": [
        {
          "name": "Tovorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Day One Biopharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2021-07-15",
      "completion_date": "2024-07-08",
      "has_results": true,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-11-11T12:04:01.203Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04985604"
    },
    {
      "nct_id": "NCT07335328",
      "title": "Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-cell Non Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "1 X 10^6 cells/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "2.5 X 10^6 cells/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose expansion: The maximum tolerated dose of CAR-T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 24,
      "start_date": "2026-11-01",
      "completion_date": "2031-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-11-11T12:04:01.203Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07335328"
    },
    {
      "nct_id": "NCT06480565",
      "title": "A Phase 1 Trial of ADI-270 in ccRCC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "ADI-270",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adicet Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2024-12-12",
      "completion_date": "2025-07-22",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-11T12:04:01.203Z",
      "location_count": 1,
      "location_summary": "Redwood City, California",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06480565"
    },
    {
      "nct_id": "NCT00935792",
      "title": "Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 28,
      "start_date": "2009-07",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-09-26",
      "last_synced_at": "2026-11-11T12:04:01.203Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00935792"
    }
  ]
}